Cilostazol and Aspirin in Stroke and TIA

Inclusion Criteria:

• Diagnosis of an acute minor ischemic stroke or TIA

• Acute minor stroke was defined by a score of 3 or less at the time of randomizationon the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42,with higher scores indicating greater deficits)

Exclusion Criteria:

• Intracerebral Hemorrhage

• Brain tumor

• Brain abscess, or other major non-ischemic brain disease;

• Isolated sensory symptoms (numbness, isolated visual changes, or isolated dizzinessor vertigo) without evidence of acute infarction on baseline CT or MRI of the head

• A score of more than 2 on the modified Rankin scale, immediately before theoccurrence of the index ischemic stroke or TIA, indicating moderate disability orworse at baseline

• An NIHSS score of 4 or more at randomization

• A clear indication for anticoagulation therapy (presumed cardiac source of embolus,such as atrial fibrillation or prosthetic cardiac valve) or a contraindication toclopidogrel, cilostazol or aspirin

• History of intracranial hemorrhage

• Anticipated requirement for long-term non-study antiplatelet drugs or fornonsteroidal anti-inflammatory drugs affecting platelet function

• Heparin therapy or oral anticoagulation therapy within 10 days before randomization

• Gastrointestinal bleeding or major surgery within the previous 3 months

• Planned or probable revascularization (any angioplasty or vascular surgery) within 3months after screening (if clinically indicated, vascular imaging was to beperformed before randomization, whenever possible)

• Planned surgery or interventional treatment requiring cessation of the study drug

• TIA or minor stroke caused by angiography or surgery

• Severe non- cardiovascular coexisting condition, with a life expectancy of less than 3 months